Navigation Links
CellMax Life to Present Expanded Test Results For Colorectal Cancer Prevention
Date:1/14/2019

CellMax Life, a diagnostics company with a proprietary technology to detect precancer and cancer cells in blood, will present new findings at the ASCO Gastrointestinal Cancer Symposium in San Francisco this month, revealing significant advancement in the fight against colorectal cancer. The results from this study show CellMax Life’s blood test, based on its proprietary CMxTM platform, can detect pre-cancers (adenomas) with close to 90 percent accuracy (Area Under the ROC Curve).

Results of the study show that based on enumeration of pre-cancer cells, it is possible to accurately differentiate between healthy patients and those with pre-cancer. Further, an increase in cell count was significantly correlated with an increase in disease severity.

“Colorectal cancer is the second deadliest cancer in the U.S., with 150,000 new cases and $14 billon spent on treatment annually,” said Atul Sharan, Co- Founder and CEO of CellMax Life. “We’re working to change that. Colorectal cancer is preventable when adenomas are detected and removed. In fact, adenoma removal reduces mortality rates from colorectal cancer by 53 percent. CellMax Life’s FirstSightCRC test will increase compliance with colorectal cancer screenings and increase detection rates at the adenoma stage, saving lives.”

The FirstSightCRC TM test detects pre-cancer and cancer cells in blood. The test utilizes a patented technology comprising a micro-fluidic chip with proprietary nano (non-sticky) layer for cell capture, high-affinity antibodies, and a special air-foam release technology to gently release the captured cells enabling high intact cell preservation, and thereby high detection rates of pre-cancer.

The IRB-approved study included 737 adults, 50 years of age or older - a population recommended routine screening by most U.S. guidelines. Of those, 301 were found to be healthy, 111 pre-cancerous (had adenoma) and 325 were confirmed to have cancer. Diseased patients were confirmed by colonoscopy or tumor biopsy. The test results presented a high accuracy for detecting colorectal cancer, with a close to 90 percent accuracy for pre-cancer and 95 percent accuracy for cancer. This was an expanded study; previous test results were presented at ASCO’s Gastrointestinal Symposium in 2018.

“Colon cancer screening is essential to detect and remove pre-cancer polyps,” said Dr Shai Friedland, Chief of Gastroenterology at the Stanford Veterans Administration and lead PI for the ongoing Zenith study to seek FDA-approval for the FirstSightCRC test. “These results are very exciting, as for the first time my patients who are reluctant to undergo a colonoscopy may have a highly sensitive non-invasive testing option for pre-cancer.”

Colorectal cancer incidence is rising among younger adults. New guidelines from the American Cancer Society recommend screening for colorectal cancer starting at age 45, down from 50 years. This means that 20 million from the age of 45-50 are newly eligible for testing. But a shocking 33 million of the eligible 100 million in the 50+ age group have never been tested.

Until now, colonoscopy has been the only screening method with the sensitivity to accurately detect adenomas. Unfortunately, due to its invasive nature only 38 percent of Americans seek this method of screening. Non-invasive options exist that are either stool or blood based; however, these tests miss a majority of pre-cancers, eliminating their preventive role per gastroenterology guidelines.

CellMax Life is poised to change that with the release of these new findings on the effectiveness of its FirstSightCRC test, a first of its kind non-invasive blood test that detects adenomas with the highest accuracy.

About CellMax Life
CellMax Life is a diagnostics company focused on cancer screening with a proprietary technology for detecting precancer and cancer cells in a single blood sample. CellMax Life is headquartered in Sunnyvale, California, and has a CLIA certified and CAP accredited laboratory at this location. For more information, visit https://cellmaxlife.com.

Read the full story at https://www.prweb.com/releases/cellmax_life_to_present_expanded_test_results_for_colorectal_cancer_prevention/prweb16030917.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Concerto HealthAI to Present at J.P. Morgan’s 37th Annual Healthcare Conference
2. Ambry Genetics Presents Research on the Importance of Reclassifying Disease-Causing Genes at the National Society of Genetic Counselors (NSGC) Annual Meeting
3. Pharmafusion CEO To Be Featured Presenter at CBI Gross-to-Net Summit
4. Horizon Discovery Presents an Educational Webinar on CRISPR-Cas9 Genome Engineering in Primary T cells
5. BRAG Requests that EPA Adopt TSCA Inventory Representation and Equivalency For Renewable and Sustainable Biobased Chemicals
6. The 5th Annual Mobile in Clinical Trials Event Presents Agenda for September 24, 2018
7. Crossmatch Awarded $5.8 Million IARPA Contract to Develop Next-Gen Biometric Presentation Attack Detection Technologies
8. Zimmer Biomet Holdings to Present at the LEERINK Partners 6th Annual Global Healthcare Conference
9. Biometrics, Borders, and Extreme Vetting in the Age of Trump; More than 3500 Automated Border Control eGates and Kiosks Now Deployed Representing 37% CAGR in Three Years
10. DERMALOG Presents the Worlds First Combined Fingerprint and Passport Scanner
11. DERMALOG présente le premier scanner couplé au monde à numériser à la fois empreintes digitales et passeports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2019)... ... ... Dr. Beanlands is the Vered Chair and Division Head of Cardiology at the ... of its National Cardiac PET Centre, and Professor in the University's Division of Cardiology ... of Cellular and Molecular medicine. , He is a founding member of ASNC, member ...
(Date:1/8/2019)... (PRWEB) , ... January 07, 2019 , ... Join industry ... Ridge for a live webinar on Thursday, January 17, 2019 at 1pm ... ongoing management of risk during the clinical trial process. Featured speakers will also present ...
(Date:1/7/2019)... ... January 07, 2019 , ... Concerto HealthAI, ... for precision health in oncology and other key therapeutic areas, and its Chief ... investors, entrepreneurs and executives spanning the entire healthcare landscape, on January 8, 2019, ...
Breaking Biology News(10 mins):
(Date:2/2/2019)... ... ... The top tech companies advancing artificial intelligence and data science are joining ... gathering of software engineers, data scientists and business executives. , Leaders in the ... Open Data Science Conference (ODSC) to demo software platforms at the event’s AI ...
(Date:2/2/2019)... ... February 01, 2019 , ... Biomatlante, ... appointment of its new CEO, Julien Dert, being effective on February 1st, 2019. ... in finance and management, in which more than 12 years in the Medical ...
(Date:1/30/2019)... ... January 29, 2019 , ... Mr. ... 2016. In his position as Director of Sales and Marketing, Mr. Schieving was ... across multiple industries the company supports. During this time, Mr. Schieving was responsible ...
(Date:1/30/2019)... Mass. (PRWEB) , ... January 29, 2019 , ... ... tell when someone is frustrated over something like a tricky math problem on ... research team led by Worcester Polytechnic Institute (WPI) computer science assistant professor ...
Breaking Biology Technology: